Table 1.
Baseline demographic and disease characteristics
| Placebo n = 84 | Apremilast | ||
|---|---|---|---|
| 20 mg b.i.d. n = 85 | 30 mg b.i.d. n = 85 | ||
| Age, mean (SD), years | 48.3 (12.0) | 52.2 (12.5) | 51.7 (12.7) |
| Male, n (%) | 62 (73.8) | 69 (81.2) | 71 (83.5) |
| BMI, mean (SD), kg/m2 | 24.7 (4.7) | 25.8 (4.2) | 24.9 (3.7) |
| Weight, mean (SD), kg | 68.5 (13.8) | 71.2 (12.9) | 70.1 (13.0) |
| Duration of psoriasis, mean (SD), years | 12.4 (9.4) | 12.6 (10.6) | 13.9 (9.2) |
| PASI score (0–72), mean (SD) | 19.9 (8.9) | 22.1 (9.6) | 21.6 (8.9) |
| PASI score >20, n (%) | 28 (33.3) | 41 (48.2) | 38 (44.7) |
| BSA, mean (SD), % | 28.0 (15.4) | 32.0 (17.5) | 30.7 (16.1) |
| BSA >20%, n (%) | 51 (60.7) | 54 (63.5) | 58 (68.2) |
| sPGA = 3 (moderate), n (%) | 49 (58.3) | 46 (54.1) | 40 (47.1) |
| sPGA = 4 (marked), n (%) | 15 (17.9) | 24 (28.2) | 25 (29.4) |
| sPGA = 5 (severe), n (%) | 4 (4.8) | 1 (1.2) | 6 (7.1) |
| DLQI score (0–30), mean (SD) | 7.5 (5.3) | 7.4 (5.6) | 7.4 (5.7) |
| Pruritus VAS (0–100 mm), mean (SD) | 57.1 (26.7) | 49.9 (26.6) | 53.1 (28.6) |
| Prior use of biologic therapy, n (%) | 4 (4.8) | 3 (3.5) | 2 (2.4) |
| Prior use of conventional systemic medications, n (%) | 22 (26.2) | 34 (40.0) | 26 (30.6) |
The n reflects the number of randomized patients; actual number of patients available for each parameter may vary. BMI, body mass index; BSA, body surface area; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; sPGA, static Physician Global Assessment; SD, standard deviation; VAS, visual analog scale.